Sanofi India planning to lower price of Rifapentine

31 Oct 2019 Evaluate

Sanofi India is planning to lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria.

The volume-based agreement will discount the price of a three-month treatment course of Rifapentine by nearly 70 percent, from approximately $45 to $15 (ex works) in the public sectors of 100 low and middle-income countries burdened by TB and TB/HIV coinfection. Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world. The Indian government has set ambitious targets to eliminate TB by 2025.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

4079.15 -79.45 (-1.91%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×